Thymus cancer

Summary

Thymus cancer (MONDO:0002586) is a cancer and 13 clinical trials. Top therapeutic interventions include bosutinib, pembrolizumab, and amrubicin. A subtype of immune system cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 13

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	thymus cancer
Mondo ID	MONDO:0002586
DOID	DOID:3277
ICD-10-CM	C37
ICD-11	1718833206
NCIT	C4962
SNOMED CT	363434003
UMLS	C0751552
MedGen	155883
GARD	0023177
Anatomy (UBERON)	UBERON:0002370
Is cancer (heuristic)	yes

Also known as: cancer of the Thymus · cancer of Thymus · cancer of thymus · malignant neoplasm of the Thymus · malignant neoplasm of Thymus · malignant neoplasm of thymus · malignant Thymus neoplasm · malignant thymus neoplasm · malignant Thymus tumor · malignant Thymus tumour · malignant tumor of the Thymus · malignant tumor of Thymus · malignant tumour of the Thymus · malignant tumour of Thymus · thymic neoplasm · thymic tumor · thymic tumour · Thymus cancer · thymus cancer

Disease family

An umbrella term covering 2 Mondo subtypes.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › immune system cancer › thymus cancer

Related subtypes (24): lymphatic system cancer, T-cell childhood acute lymphocytic leukemia, B-cell childhood acute lymphoblastic leukemia, primary central nervous system lymphoma, solitary plasmacytoma of chest wall, dendritic cell sarcoma, Waldeyer’s ring cancer, breast diffuse large B-cell lymphoma, colon Burkitt lymphoma, colorectal diffuse large B-cell lymphoma, gastric mantle cell lymphoma, liver diffuse large B-cell lymphoma, primary pulmonary diffuse large B-cell lymphoma, small intestinal Burkitt lymphoma, small intestinal diffuse large B-cell lymphoma, small intestinal enteropathy-associated T-cell lymphoma, thyroid gland diffuse large B-cell lymphoma, plasma cell myeloma, indolent primary cutaneous B-cell lymphoma, systemic Epstein-Barr virus-positive T-cell lymphoproliferative disease of childhood, mast cell sarcoma, subcutaneous panniculitis-like T-cell lymphoma, bone marrow cancer, primary vitreoretinal large b-cell lymphoma

Subtypes (2): thymus lymphoma, thymic carcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 13.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	7
PHASE2	4
PHASE1	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05683886	PHASE2	RECRUITING	A Study of KC1036 in Patients with Advanced Thymic Tumors
NCT00990535	PHASE2	COMPLETED	High Dose Somatostatin Analogues in Neuroendocrine Tumors
NCT01364727	PHASE2	COMPLETED	A Phase 2 Study of Amrubicin in Relapsed or Refractory Thymic Malignancies
NCT02364076	PHASE2	UNKNOWN	Pembrolizumab and Epacadostat in Patients With Thymic Carcinoma
NCT04459273	PHASE1	ACTIVE_NOT_RECRUITING	Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers
NCT03023319	PHASE1	COMPLETED	Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors
NCT01385722	Not specified	ENROLLING_BY_INVITATION	Molecular Analysis of Thoracic Malignancies
NCT02012699	Not specified	RECRUITING	Integrated Cancer Repository for Cancer Research
NCT06996249	Not specified	RECRUITING	Prospective Data Collection Initiative on Thoracic Malignancies
NCT07072143	Not specified	RECRUITING	An International Study on Pediatric Patients With Rare Tumors.
NCT01135849	Not specified	COMPLETED	B-Receptor Signaling in Cardiomyopathy
NCT03078699	Not specified	COMPLETED	Prospective Study of Stereotactic Body Radiation Therapy for Thymoma Inoma: Therapeutic Effect and Toxicity Assessment
NCT04028479	Not specified	COMPLETED	The Registry of Oncology Outcomes Associated With Testing and Treatment

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
BOSUTINIB	4	1
PEMBROLIZUMAB	4	1
AMRUBICIN	3	1
EPACADOSTAT	3	1
FAPI-46 GA-68	2	1
CHEMBL4067978	0	1